GlassScriptPhysician profile
Lisa V Suffian
NPI 1578510509
$4,696.37
in general payments reported to CMS, 2019-2025
30 companies · $1,517 in 2025
The $1,517 reported for 2025 was more than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $108 · 2021: $178 · 2022: $503 · 2023: $807 · 2024: $920 · 2025: $1,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,130 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,129.91 |
| Education | $113.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,032.99 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $761.47 | 2019-2025 | Dupixent |
| Genzyme Corporation | $465.86 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $414.36 | 2019-2025 | |
| Glaxosmithkline, LLC. | $407.11 | 2019-2025 | Nucala |
| Genentech USA, INC. | $292.43 | 2023-2025 | Xolair |
| Kaleo, INC. | $235.13 | 2019-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $149.60 | 2025 | Neffy |
| Csl Behring | $98.46 | 2019-2025 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $90.62 | 2025 | Eohilia, Cuvitru, Hyqvia |
| Sanofi-Aventis U.S. LLC | $79.99 | 2023 | |
| Abbvie INC. | $77.23 | 2023-2024 | Rinvoq |
| Amgen INC. | $73.17 | 2023-2025 | Tezspire |
| Organon LLC | $49.91 | 2025 | |
| Lilly USA, LLC | $49.09 | 2024-2025 | Ebglyss, Zepbound, Taltz |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $46.45 | 2021 | |
| Grifols USA, LLC | $44.88 | 2023-2025 | Xembify |
| Pfizer INC. | $43.78 | 2021-2025 | |
| Gc Biopharma USA, INC. | $35.26 | 2025 | Alyglo |
| Optinose US, INC. | $33.37 | 2025 | |
| Aimmune Therapeutics, INC. | $29.58 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $27.05 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.52 | 2019-2021 | |
| Kedrion Biopharma, INC. | $22.98 | 2024 | Gammaked, Rhogam Ultra-Filtered Plus, Albuked |
| Galderma Laboratories, L.P. | $21.98 | 2025 | Nemluvio |
| Merck Sharp & Dohme LLC | $21.87 | 2019 | |
| Leo Pharma INC. | $21.13 | 2025 | Anzupgo |
| Hikma Pharmaceuticals USA | $18.12 | 2023 | Ryaltris |
| Azurity Pharmaceuticals, INC. | $14.37 | 2025 | Alvesco |
| Alk-Abello, INC | $13.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Suffian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.